Zydus Lifesciences Limited
ZYDUSLIFE
Rankning i aktier
#1795
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Aktiekurs
$11.90
Marknadsvärde
$11.87B
Förändring (1 dag)
-3.28%
Förändring (1 år)
4.77%
Land
IN
Handel Zydus Lifesciences Limited (ZYDUSLIFE)
Kategori
Healthcare
Vinst för Zydus Lifesciences Limited (ZYDUSLIFE)
Vinst i Jun 2026 TTM: $674.03M
Enligt de senaste finansiella rapporterna från Zydus Lifesciences Limited är företagets nuvarande vinst $674.03M. År 2024 hade företaget en vinst på $590.92M, en ökning jämfört med vinsten år 2023 som var $326.63M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Zydus Lifesciences Limited från 2004 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $674.03M | -5.26% |
| 2025 | $711.42M | 20.39% |
| 2024 | $590.92M | 80.91% |
| 2023 | $326.63M | -14.04% |
| 2022 | $379.97M | 13.69% |
| 2021 | $334.22M | 65.19% |
| 2020 | $202.32M | -42.16% |
| 2019 | $349.80M | -4.85% |
| 2018 | $367.62M | 44.63% |
| 2017 | $254.19M | -21.37% |
| 2016 | $323.28M | 39.35% |
| 2015 | $231.99M | 47.59% |
| 2014 | $157.19M | 5.61% |
| 2013 | $148.84M | -4.97% |
| 2012 | $156.62M | -17.15% |
| 2011 | $189.05M | 40.60% |
| 2010 | $134.46M | 84.59% |
| 2009 | $72.84M | -9.87% |
| 2008 | $80.82M | 27.90% |
| 2007 | $63.19M | 59.18% |
| 2006 | $39.70M | 26.43% |
| 2005 | $31.40M | -10.04% |
| 2004 | $34.90M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 161.79% |
IN
|
